Роль нейрегулинов и фактора роста гепатоцитов в развитии кастрационно-рефрактерного рака предстательной железы

Роль нейрегулинов и фактора роста гепатоцитов в развитии кастрационно-рефрактерного рака предстательной железы

Автор: Спирина Людмила Викторовна, Усынин Евгений Анатольевич, Слонимская Елена Михайловна, Кондакова Ирина Викторовна, Горбунов А.К.

Журнал: Сибирский онкологический журнал @siboncoj

Рубрика: Обзоры

Статья в выпуске: 4 (70), 2015 года.

Бесплатный доступ

Развитие кастрационно-резистентного рака предстательной железы является важной проблемой современной онкологии, ухудшающей течение и качество жизни пациентов. Основное внимание в обзоре сосредоточено на системе ростовых факторов - нейрегулинов и факторе роста гепатоцитов (HGF) - непосредственных лигандов тирозиновых протеинкиназ ErbB и рецептора фактора роста гепатоцитов c-Met, активация которых запускает каскад сигнальных путей, завершающийся стимуляцией пролиферации раковых клеток, их миграцией в условиях развития нечувствительности к кастрационному лечению.

Рак предстательной железы, нейрегулины

Короткий адрес: https://sciup.org/14056566

IDR: 14056566

Список литературы Роль нейрегулинов и фактора роста гепатоцитов в развитии кастрационно-рефрактерного рака предстательной железы

  • Спирина Л.В., Кондакова И.В., Усынин Е.А., Коломиец Л.А., Чойнзонов Е.Л., Мухамедов М.Р., Чернышова А.Л., Шарова Н.П. Активность протеасом в тканях злокачественных опухолей различных локализаций//Сибирский онкологический журнал. 2009. № 5. С. 49-52.
  • Ancot F., Leroy C., Muharram G., Lefebvre J., Vicogne J., Lemiere A., Kherrouche Z., Foveau B., Pourtier A., Melnyk O., Giordano S., Chotteau-Lelievre A., Tulasne D. Shedding-generated Met receptor fragments can be routed to either the proteasomal or the lysosomal degradation pathway//Traffic. 2012. Vol. 13 (9). P. 1261-1272 DOI: 10.1111/j.1600-0854.2012.01384.x
  • Bachleitner-Hofmann T., Sun M.Y., Chen C.T., Tang L., Song L., Zeng Z., Shah M., Christensen J.G., Rosen N., Solit D.B., Weiser M.R. HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells//Mol. Cancer Ther. 2008. Vol. 7 (11). P. 3499-3508 DOI: 10.1158/1535-7163.MCT-08-0374
  • Barnes C.J., Li F., Talukder A.H., Kumar R. Growth factor regulation of a 26S proteasomal subunit in breast cancer//Clin. Cancer Res. 2005. Vol. 11 (8). P. 2868-2874.
  • Basilico C., Arnesano A., Galluzzo M., Comoglio P.M., Michieli P. A high affinity hepatocyte growth factor-binding site in the immunoglobulinlike region of Met//J. Biol. Chem. 2008. Vol. 283. P. 21267-21277.
  • Carrion-Salip D., Panosa C., Menendez J.A., Puig T., Oliveras G., Pandiella A., De Llorens R., Massaguer A. Androgen-independent prostate cancer cells circumvent EGFR inhibition by overexpression of alternative HER receptors and ligands//Int. J. Oncol. 2012. Vol. 41 (3). P. 1128-1138 DOI: 10.3892/ijo.2012.1509
  • Chang H., Riese D.J., Gilbert W., Stern D.E., McMahan U.J. Ligands for ErbB-family receptors encoded by a neuregulin-like gene//Nature. 1997. Vol. 387. P. 509-512.
  • Comoglio P.M., Giordano S., Trusolino L. Drug development of MET inhibitors: targeting oncogene addiction and expedience//Nat. Rev. Drug Discov. 2008. Vol. 7. P. 504-516.
  • Cruz J.J., Ocana A., Del Barco E., Pandiella A. Targeting receptor tyrosine kinases and their signal transduction routes in head and neck cancer//Ann. Oncol. 2007. Vol. 18. P. 421-430.
  • Garcia-Guzman M., Dolfi F., Zeh K., Vuori K. Met-induced JNK activation is mediated by the adapter protein Crk and correlates with the Gab1 -Crk signaling complex formation//Oncogene. 1999. Vol. 1. P. 7775-7786.
  • Grimsley S.J., Shini S., Underwood M.A., Edwards J. Heregulin expression and prognosis in prostate adenocarcinoma//Urol. Int. 2011. Vol. 87 (3). P. 363-368 DOI: 10.1159/000328627
  • Groenen L.C., Nice E.C., Burgess A.W. Structure-function relationships for the EGF/TGF-alpha family of mitogens//Growth Factors. 1994. Vol. 11. P. 235-257.
  • Harari D., Tzahar E., Romano J., Shelly M., Pierce J.H., Andrews G.C., Yarden Y. Neuregulin-4: a novel growth factor that acts through the ErbB-4 receptor tyrosine kinase//Oncogene. 1999. Vol. 18. P. 2681-2689.
  • Humphrey P.A., Halabi S., Picus J., Sanford B., Vogelzang N.J., Small E.J., Kantoff P.W. Prognostic significance of plasma scatter factor/hepatocyte growth factor levels in patients with metastatic hormonerefractory prostate cancer: results from cancer and leukemia group B 150005/9480//Clin. Genitourin. Cancer. 2006. Vol. 4. P. 269-274.
  • Hynes N.E., Lane H.A. ERBB receptors and cancer: the complexity of targeted inhibitors//Nat. Rev. Cancer. 2005. Vol. 5. P. 341-354.
  • Jefferd M., Taylir M., Weidner K.M., Omura S., Vande Wiude G.F. Degradation of the Met tyrosine kinase receptor by the ubiquitin-proteasome pathway//Mol. Cell Biol. 1997. Vol. 17 (2). P. 799-808.
  • Jo M., Stolz D.B., Esplen J.E., Dorko K., Michalopoulos G.K., Strom S.C. Cross-talk between epidermal growth factor receptor and c-Met signal pathways in transformed cells//J. Biol. Chem. 2000. Vol. 275. P. 8806-8811.
  • Kehinde E.O., Maghrebi M.A., Anim J.T. The importance of determining the aggressiveness of prostate cancer using serum and tissue molecular markers//Can. J. Urol. 2008. Vol. 15 (2). P. 3967-3974.
  • Knudsen B.S., Edlund M. Prostate cancer and the met hepatocyte growth factor receptor//Adv. Cancer Res. 2004. Vol. 91. P. 31-67.
  • Lai A.Z., Abella J.V., Park M. Crosstalk in Met receptor oncogenesis//Trends Cell Biol. 2009. Vol. 19 (10). P. 542-551 DOI: 10.1016/j.tcb.2009.07.002
  • Lee R.J., Smith M.R. Targeting MET and VEGFR Signaling in Castration-Resistant Prostate Cancer//Cancer J. 2013. Vol. 19 (1). P. 90-98.
  • Li C., Ma J., Zhao H., Blagg B.S., Dobrowsky R.T. Induction of heat shock protein 70 (Hsp70) prevents neuregulin-induced demyelination by enhancing the proteasomal clearance of c-Jun//ASN Neuro. 2012. Vol. 4 (7). P. 425-437 DOI: 10.1042/20120047
  • Li J.X., Fei X.M., Lu H., Hu H.J., Li J.Y. Effect of proteasome inhibitor on migration ability and hepatocyte growth factor expression of bone marrow mesenchymal stem cells in multiple myeloma patients//Zhongguo Shi Yan Xue Ye Za Zhi. 2011. Vol. 19 (5). P. 1204-1208.
  • Magnifico A., Tagliabue E., Ardini E., Casalini P., Colnaghi M.I., Menaed S. Heregulin beta1 induces the down regulation and the ubiquitinproteasome degradation pathway of p185HER2 oncoprotein//FEBS Lett. 1998. Vol. 422 (2). P. 129-131.
  • Montero J.C., Rodriguez-Barrueco R., Ocana A., Diaz-Rodriguez E., Wsparis-Ogando A., Pandiella A. Neuregulins and cancer//Clin. Cancer Res. 2008. Vol. 14 (11). P. 3237-3241.
  • Naughton M., Picus J., Zhu X., Catalona W.J., Vollmer R.T., Humphrey P.A. Scatter factor-hepatocyte growh factor elevation in the serum of patients with prostate cancer//J. Urol. 2001. Vol. 165. P. 1325-1328.
  • Paumelle R., Tulasne D., Kherrouche Z., Plaza S., Leroy C., Reveneau S., Vandenbunder B., Fafeur V. Hepatocyte growth factor/scatter factor activates the ETS1 transcription factor by a RAS-RAF-MEK-ERK signaling pathway//Oncogene. 2002. Vol. 21. P. 2309-2319.
  • Pfeil K., Edel I.E., Putz T., Ramonet R., Culig Z., Ueberall F., Bartsch G., Klocker H. Long-term androgen-ablation causes increased resistance to PI3K/Akt pathway inhibition in Prostate cancer cells//Prostate. 2004. Vol. 58 (3). P. 259-268.
  • Pignon J.C., Koopmansch B., Nolens G., Delacroix L., Waltregny D., Winkler R. Androgen receptor controls EGFR and ERBB2 gene expression at different levels in prostate cancer cell lines//Cancer Res. 2009. Vol. 69 (7). P. 2941-2949 DOI: 10.1158/0008-5472.CAN-08-3760
  • Ryan C.J., Rosenthal M., Ng S., Alumkal J., Picus G., Gravis G., Fizazi K., Forget F., Machiels J.P., Srinivas S., Zhu M., Nabg R., Oliner K.S., Jiang Y., Loh E., Dubey S., Gerritsen W.R. Targeted MET inhibition in castration-resistant prostate cancer: a randomized phase II study and biomarker analysis with rilotumumab plus mitoxantrone and prednisone//Clin. Cancer Res. 2013. Vol. 19 (1). P. 215-224 DOI: 10.1158/1078-0432.CCR-12-2605
  • Schmukler E., Shai B., Ehrlich M., Pinkas-Kramarski R. Neuregulin promotes incomplete autophagy of prostate cancer cells that is independent of mTOR pathway inhibition//PloS One. 2012. Vol. 7 (5). e36828 DOI: 10.1371/journal.pone.0036828
  • Shimizu H., Seiki T., Asada M., Yoshimatsu K., Koyama N. Alpha6-beta1 integrin induces proteasome-mediated cleavage of erbB2 in breast cancer cells//Oncogene. 2003. Vol. 22 (6). P. 831-839.
  • Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene//Science. 1987. Vol. 235. P. 177-182.
  • Syed Z.A., Yin W., Hughes K., Gill J.N., Shi R., Clifford J.L. HGF/c-met/Stat3 signaling during skin tumor cell invasion: indications for a positive feedback loop//BMC Cancer. 2011. Vol. 11. P. 180 DOI: 10.1186/1471-2407-11-180
  • Tinz M., Chtn B., Chqn S.Y., Semenas J., Abrahamson P.A., Diveyi N. Interaction between c-jun and androgen receptor determines the outcome of taxane therapy in castration resistant prostate cancer//Plos One. 2013. Vol. 8 (11). e79573 DOI: 10.1371/journal.pone.0079573
  • Tu W.H., Zhu C., Clark C., Christensen J.C., Sun Z. Efficacy of c-Met inhibitor for advanced prostate cancer//BMC Cancer. 2010. Vol. 10. P. 556 DOI: 10.1186/1471-2407-10-556
  • Wicha M.S. B4 androgen ablation: attacking the prostate cancer stem cell//J. Clin. Invest. 2013. Vol. 123 (2). P. 563-565 DOI: 10.1172/JCI67460
  • Xiao G.H., Jeffers M., Bellacosa A., Mitsuuchi Y., Vande Woude G.F., Testa J.R. Anti-apoptotic signaling by hepatocyte growth factor/Met via the phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase pathways//Proc. Natl. Acad. Sci. USA. 2001. Vol. 98. P. 247-252.
  • Yeh C.Y., Shin S.M., Yeh H.H., Wu T.J., Shin J.W., Chang T.Y. Transcriptional activation of the Axl and PDGFR-alpha by c-Met through a ras-and Src-independent mechanism in human bladder cancer//BMC Cancer. 2011. Vol. 11. P. 139 DOI: 10.1186/1471-2407-11-139
  • Yonezawa M., Wada K., Tatsuguchi A., Akamatsu A., Gudis K., Seo T., Mitsui K., Nagata K., Tanaka S., Fujimori S., Sakamoto C. Heregulin-induced VEGF expression via the ErbB3 signaling pathway in colon cancer//Digestion. 2009. Vol. 80 (4). P. 215-225 DOI: 10.1159/000229775
  • Yu H., Li X., Sun S., Gao X., Zhou D. c-Met inhibitor SU11274 enhances the response of the prostate cancer cell line DU145 to ionizing radiation//Biochem. Biophys. Res. Commun. 2012. Vol. 427 (3). P. 659-665 DOI: 10.1016/j.bbrc.2012.09.117
  • Zhang D., Sliwkowski M.X., Mark M., Frantz G., Akita R., Sun Y., Jillan K., Crowley C., Brush J., Godowski P.J. Neuregulin-3 (NRG3): a novel neural tissue-enriched protein that binds and activates ErbB4//PNAS (USA). 1997. Vol. 94 (18). P. 9562-9567.
  • Zhou H., Zhang Y., Hamburger A.W. EBP1 inhibits translation of androgen receptor mRNA in castration resistant prostate cancer cells//Anticancer Res. 2011. Vol. 31 (10). P. 3129-3135.
Еще
Статья обзорная
SciUp 2024 © 2024 ©